Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…
Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…
Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…
NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…